



A French « Société anonyme » with a Board of Directors and a share capital of 13 704 097 euros
Headquarters : 49 boulevard du Général Martial Valin, 75015 Paris
410 910 095 R.C.S. Paris

ANNUAL GENERAL MEETING - APRIL 26, 2019

OFFICES AND FUNCTIONS PERFORMED BY THE DIRECTORS OF THE COMPANY IN 2018

We disclose the following list of all the offices and functions held by each of the Company directors during the year in all French or foreign companies. This description is extended to the last five years to comply with Annex I of Regulation (EC) 809/2004 that governs the drafting of registration documents. The other offices and/or functions of the directors indicated below are on the basis of the declarations of the interested parties. The Company specifies that it may not be held liable for the information provided by the directors or corporate officers.

Director	Offices and mandates
<p>Joseph Zakrzewski</p> <p>Joseph Zakrzewski has served as Chairman of Onxeo since 22 January 2016. His term of office will expire at the General Meeting of Shareholders of 2019.</p> <p>Born on 30/12/1962, Mr Zakrzewski has over 25 years of experience in the biotechnology and the pharmaceutical industries. He is a member of the Board of Directors of several listed and unlisted companies. He advises many entities, and also engages in various philanthropic activities.</p> <p>Mr. Zakrzewski was a Venture Partner in 2010 and 2011 at Orbimed, the largest fund dedicated to health in the world. From 1988 to 2004, Mr. Zakrzewski held various positions at Eli Lilly & Company, especially in R&D, production, finance, and business development for the biotechnology and protein divisions.</p> <p><u>Business address</u> 715 Street Road, New Hope, PA 18938 United States</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none">• Chairman of the Board of Directors of Onxeo SA <p><u>Outside the Company</u></p> <ul style="list-style-type: none">• Director of Acceleron Pharmaceuticals Inc. (USA)• Director of Amarin Pharmaceuticals Inc. (USA)• Director of Sangamo Therapeutics (USA) <p><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul style="list-style-type: none">• Director of Liposcience Inc. (USA)• Director of I Corporation (USA)• Director of Insulet Corporation (USA)

<p>Judith GRECIET</p> <p>Judith Greciet joined Onxeo on 1 March 2011, as Chief Operating Officer in charge of R&D and Operations. She has been Chief Executive Officer and a Director of the company since 29 June 2011. Her term of office will expire at the shareholders' general meeting of 2020.</p> <p>Born on 10/27/1968, Judith Greciet's career has been spent in various laboratories (including Eisai, Zeneca, and Wyeth), occupying important managerial and strategic international positions in the growing field of oncology and immunology, and working on innovative products. She has a PhD in Pharmacy and is a graduate in business administration and pharmaceutical marketing.</p> <p><u>Business address:</u> ONXEO 49, Boulevard du Général Martial Valin 75015 Paris France</p>	<p>Offices and mandates</p> <p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director and Chief Executive Officer of Onxeo SA <p><u>Outside the Company</u></p> <ul style="list-style-type: none"> • President of Onxeo Inc. (United States) <p><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul style="list-style-type: none"> • Director of Theravectys SA, France • Chairman of Laboratoires BioAlliance Pharma SA
<p>Danièle Guyot-Caparrós</p> <p>Danielle Guyot-Caparrós is a Director of Onxeo since 26 June 2013. Her term of office will expire at the General Meeting of Shareholders of 2019.</p> <p>Born on 10/16/1958, Danielle Guyot-Caparrós started her career with an audit firm carrying out international assignments, and then joined Rhône-Poulenc, later to become Aventis and then Sanofi, occupying several important posts, notably with responsibilities carried out in France at European level, in business planning and performance monitoring on a worldwide level.</p> <p>Senior Life Sciences Advisor for Deloitte since 2008, she holds a Master's degree in Finance/Accounting as well as a DECF (Diploma in Public Accounting).</p> <p><u>Business address</u> 4, rue Eblé 75007 Paris France</p>	<p>Offices and mandates</p> <p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director of Onxeo SA <p><u>Outside the Company</u></p> <ul style="list-style-type: none"> • Administrator of Supersonic imaging SA (France) <p><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul style="list-style-type: none"> • Member of the supervisory board of Diaxonhit SA (France)

Director	Offices and mandates
<p data-bbox="196 244 416 271">Christine GARNIER</p> <p data-bbox="196 315 715 443">Christine Garnier has been a Director of Onxeo since 26 April 2017. Her term of office will expire at the General Meeting of Shareholders of 2020.</p> <p data-bbox="196 488 715 1529">Born on 28/02/1961, Christine Garnier is co-founder of the firm AEC Partners and has been Managing Partner since 1998. A graduate of ESCP Europe, her consultant activity is specialized in corporate, international and operational strategies, evolutions in business models and organizations, and the optimization of performance across the life science industry. During the last twenty years, Christine Garnier has managed more than 200 assignments on primary and specialty care products, vaccine products, as well as medical devices and OTC. She supports executive committees and operational and functional management in the development of vision, their strategies and changes to their organizations. The perimeters of her interventions concentrate on Europe and fast developing countries (South East Asia, Latin America etc.) as well as international and corporate headquarters. She provides her clients with strong expertise in strategy and organization, coupled with her skill to identify and initiate necessary transformations. Before joining AEC Partners, Christine Garnier previously worked for 12 years in the pharmaceutical industry holding marketing positions in Wyeth and international marketing and strategic planning at Rhône Poulenc Rorer.</p> <p data-bbox="196 1574 549 1736"><u>Business address:</u> AEC Partners 27 avenue Pierre 1er de Serbie 75116 Paris France</p>	<p data-bbox="727 244 963 271"><u>Within the Company</u></p> <ul data-bbox="754 282 1034 309" style="list-style-type: none"> • Director of Onxeo SA <p data-bbox="727 349 975 376"><u>Outside the Company</u></p> <ul data-bbox="754 387 1394 517" style="list-style-type: none"> • Managing director of AEC General Partners (Private company) • Managing director of AEC Limited (Private Company) • Director of AEC Asia (Private company) <p data-bbox="727 562 1394 618"><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul data-bbox="754 629 855 656" style="list-style-type: none"> • None

Director	Offices and mandates
<p data-bbox="196 241 438 271">Elvira SANZ URGOITI</p> <p data-bbox="196 311 715 409">Elvira Sanz has been a Director of Onxeo since 26 April 2017. Her term of office will expire at the General Meeting of Shareholders of 2020.</p> <p data-bbox="196 450 715 784">Born on 10/04/1959, Elvira Sanz is a Doctor in Pharmacy who graduated from the Complutense University of Madrid, with Extraordinary Prize of End of Career and graduated with an International MBA from the Business School ESDEN, first in her class. She has undertaken postgraduate courses at prestigious universities and international business schools, such as the Harvard Business School and Wharton University.</p> <p data-bbox="196 824 715 1568">She has extensive experience in the pharmaceutical industry which she has accumulated over 25 years, starting as a Research Scientist and occupying positions of growing responsibility across different business areas for MSD, Roche and Cyanamid. In 1994, she joined Wyeth Farma as Director of Registrations and New Products. In 1996, she was appointed as Marketing Director and subsequently, in 1998, Deputy Director General until 2000, when she was appointed as Director General for Spain. In 2005, she joined Wyeth's US headquarters to develop a global project, reporting to the CEO of the company, for the restructuration of Wyeth's affiliates at global level. In 2007, she returned to Spain as General Director for Spain and Portugal. Following the acquisition of Wyeth by Pfizer in October 2009, she was named President and Director General, a position she held until 2015.</p> <p data-bbox="196 1608 399 1736"><u>Business address:</u> Bolonia 1 28028 Madrid Spain</p>	<p data-bbox="727 241 965 271"><u>Within the Company</u></p> <ul data-bbox="756 280 1034 309" style="list-style-type: none"> • Director of Onxeo SA <p data-bbox="727 349 975 378"><u>Outside the Company</u></p> <ul data-bbox="756 387 1402 486" style="list-style-type: none"> • Administration Board member "Universidad Europea de Madrid" • Board member "Save the Children" <p data-bbox="727 526 1402 589"><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul data-bbox="756 598 1225 909" style="list-style-type: none"> • President Pfizer SL • President Pfizer GEP SL • President Laboratorios Parke Davis SL • President Wyeth Farma SA • President Vinci Farma SA • President Hospira Invicta SA • President Pharmacia Nostrum SA • President Binesa 2002 SL • Board member Zoetis Spain SL

Director	Offices and mandates
<p>Thomas HOFSTAETTER</p> <p>Thomas Hofstaetter has been a Director of Onxeo since 31 May 2012. His office will be proposed for renewal at the General Meeting of Shareholders of 2021.</p> <p>Born on 04/06/1948, Thomas Hofstaetter holds a doctorate in molecular biology from the University of Tubingen, Germany. He has over thirty years' experience in corporate development and mergers and acquisitions of pharmaceutical and biotechnology companies, particularly with Wyeth, Inc., Aventis, VaxInnate Corporation and Geron Corporation.</p> <p><u>Business address</u> Thomas Hofstaetter Lindenstr. 37 60325 Frankfurt Germany</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director of Onxeo SA <p><u>Outside the Company</u></p> <ul style="list-style-type: none"> • None <p><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul style="list-style-type: none"> • Director of Bionor Pharma ASA, Norway • Director of Geron Corporation, USA

Director	Terms of office and functions
<p>FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA</p> <p>Financière de la Montagne has been a Director since June 29, 2011. Its term of office will expire at the General Meeting of Shareholders of 2020.</p> <p>Born on 05/29/1963, Nicolas Trebouta, has managed investments since 2004 directly through his company, Financière de la Montagne, or through biotech funds. Co-founder of Chevrillon and Associates in 2000, he participated, via this organization, in several LBO operations including Picard Surgelés, the printer CPI, and Albingia Insurance. He is a medical doctor and has been a shareholder of Onxeo since 2008.</p> <p><u>Business address</u> Financière de la Montagne 4-6, Rond-Point des Champs Elysées 75008 Paris France</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director of Onxeo SA <p><u>Outside the Company</u></p> <ul style="list-style-type: none"> • Manager of the SARL Financière de la Montagne • Manager of the SCI Fleurus Immobilier • Manager of the SCI 5 rue de la Liberté • CEO of the SAS Dragon 8 • Managing partner of the SC Financière des Associés • Director of the GIE IO • Chairman of the Supervisory Board of the SCA Chevrillon & Associés • Manager of the EARL Ferme de Bissy • Managing Partner of the SC Valois • Manager of the SCI du Trillon • Representative of FDM, director of Onxeo (formerly Bioalliance) • Co-Manager of the SC Aster • Manager of the SCI du Chardonnet <p><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul style="list-style-type: none"> • Chairman & CEO of the SICAV Mercure Epargne Longue (dissolved in May 2014)

Director	Terms of office and functions
<p>Jean-Pierre BIZZARI</p> <p>Jean-Pierre Bizzari has been a Director since April 6, 2016. His term of office will expire at the General Meeting of Shareholders of 2019.</p> <p>Born on 10/29/1954, Doctor Jean-Pierre Bizzari was Executive Vice President and Director of clinical development in Oncology for the United States, Europe, Asia and Japan for Celgene from 2008 to 2015. He participated in the clinical development of several anti-cancer agents such as Taxotere®, Eloxatin®, Abraxane® and Irinotecan® (CPT-11). A world renowned oncology expert, he is a member of the Scientific Advisory Council of the National Institute of Cancer (INCa), of the European Organisation for the Research and Treatment of Cancer (EORTC), and President of the New Drug Advisory Committee. Dr Bizzari is also an active member of the Board of Directors of several biotechnology companies in France and the United States. He has published over 70 articles in renowned scientific journals and presented more than 160 "abstracts" at scientific congresses.</p> <p><u>Business address:</u> 100 St Georges Road Unit 4A Ardmore. 19003 PA. USA</p>	<p><u>Within the Company</u></p> <ul style="list-style-type: none"> • Director of Onxeo SA <p><u>Outside the Company</u></p> <ul style="list-style-type: none"> • Director of Transgene SA (France) • Director of Halozyme Therapeutics, Inc. (USA) • Director of Pieris Pharmaceuticals, Inc. (USA) • Director of Nordic Nanovector ASA (Public, Norway) • Director of Oxford BioTherapeutics Ltd (UK) • Director of European Organisation for Research and Treatment of Cancer (EORTC) <p><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul style="list-style-type: none"> • Director of Celator Pharmaceuticals (USA) • Director of iTeos Therapeutics (Private, Belgium)

Director	Terms of office and functions
<p data-bbox="193 241 405 271">Jean-Pierre KINET</p> <p data-bbox="193 311 715 409">Jean-Pierre Kinet has been a Director since April 6, 2016. His term of office will expire at the General Meeting of Shareholders of 2019.</p> <p data-bbox="193 448 715 1088">Born on 10/23/1953, Professor and Doctor Jean-Pierre Kinet is one of the world's most prominent experts in Immunology, mostly known for having discovered several genes and proteins constituting the immunoglobulin E-receptors. His scientific discoveries have helped introduce therapies and new diagnostic tools for the treatment of diseases related to the deregulation of the immune system. He is also co-founder and founder of two biotechnology companies and member of the Board of Directors of several other European biotechnology companies. Dr Kinet has been Professor of Pathology at Harvard Medical School in Boston, USA until January 2018. Jean-Pierre Kinet is also a member of the Scientific Advisory Committee of UCB Pharma, Managing Partner at iXLife Capital</p> <p data-bbox="193 1128 400 1158"><u>Business address:</u></p> <p data-bbox="193 1162 477 1258">1950 chemin des Lauves 13100 Aix en Provence France</p>	<p data-bbox="724 241 963 271"><u>Within the Company</u></p> <ul data-bbox="775 284 1064 313" style="list-style-type: none"> • Director of Onxeo SA <p data-bbox="724 351 975 380"><u>Outside the Company</u></p> <ul data-bbox="775 392 1382 696" style="list-style-type: none"> • Director of AB Science SA (France) • Director of Pharmaleads SA (France) • Chairman of Board of directors of Vaxon SA (France) • Chairman of Ixlife Capital SAS (France) • Member of the Board of the Harvard Institute of RNA Medicine (HIRM) • Member of the Board of the Harvard-associated BIDMC Cancer Center <p data-bbox="724 734 1402 801"><u>Other mandates and offices held over the past previous 5 years and no longer held</u></p> <ul data-bbox="775 808 1402 904" style="list-style-type: none"> • Chairman of the Board of directors of Theravectys SA (France) • Director of UCB Pharma SA (Belgium)